Vista Pharmaceuticals has completed all data filings and up to date in GDUFA fee payments for 2019 and is waiting for approval from USFDA for commercial launch of generic Dofetilide.
Vista Pharmaceuticals had filed an ANDA in September 2017 Dofetilide (Brand: TIKOSYN) in financial partnership with Biddle Sawyer, USA.
TIKOSYN (Generic: Dofetilide) is a CARDIAC drug which went OFF PATENT on October 09, 2018 and the drug molecule, TIKOSYN is owned by Pfizer.
Upon approval of Dofetilide ANDA, the company will join the exclusive club of other 4 Generic Manufacturers (Sun, Greenstone, Bion, Mayne/Sigma). The size of the market is over $ 200 million (Rs 1,400 crore approximately).
Vista Pharmaceuticals is engaged in manufacturing and selling of pharmaceutical, medical and veterinary preparations. The company also sells the products to its related companies, which are engaged in the manufacture of formulations.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: